Replies to post #188446 on Biotech Values

[DewDiligence]

ABBV/ENTA—What if EDP-239 is superior to ABT-530? Then Enta has the COMBO (ABT-493 + EDP-239) superior to Abbv's Next-Gen. Enta becomes a very attractive acquisition candidates and Abbv knows it!

It doesn’t work that way; ABT-493 has been exclusively licensed to ABBV, so it can’t be used in one of ENTA’s wholly-owned HCV regimens.